
Prime Stock Recommendation : A lesser-known niche bio-tech player
Login required to read this article.

Login required to read this article.

You would have heard fund managers talk about following a top-down and bottom-up approach. What are they? How do you use them to filter your stocks and when to use what? This article will try to touch upon some aspects of these approaches to investing, with screeners (from our own Stock Screener tool) that will illustrate and help you understand how to approach these strategies.

Value investing is often mistaken for buying ‘cheap’ stocks. Therefore, you often simply look for a stock with a low PE ratio, or a low price to book value or with good dividend yield. These are easy ways to assess the relative value of a company. But value investing is not about buying companies that appear cheap based on these parameters. Value investing is a philosophy of buying a company at a price that is lower than its intrinsic value.

Rakesh Jhunjhunwala portfolio (listed) is easily accessible, since companies need to disclose large shareholders each quarter. But it is not that easy to build your investments based on it. The reasons why it is hard to replicate the portfolio and its success are many.

For the first quarter of FY-22 listed steel stocks have generated profits that are already three-fourth that of the full year ending FY-21. The sector has thus stood out for its June quarter earnings, the 2nd wave of Covid lockdown and drop in consumption notwithstanding. Higher prices and export opportunities buttressed earnings despite a drop in domestic sales.

Federal Bank is charting a different course with a significant thrust on technology, digital adoption and diversification into new retail segments in the last five years.

Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?

A company’s Annual Report is a statutory document that contains material facts and information about the company. This makes it among the most reliable sources for information on a company. In this article, we will try to give examples of where in an annual report you can find information that is useful for your understanding of business and financials. This is an illustrative article and not an exhaustive one.

Login required to read this article.

Login required to read this article.

India Pesticides is launching an IPO totalling to Rs 800 crore – with fresh issue of shares worth Rs 100 crore and an offer for sale worth Rs 700 crore by the promoter group. At the upper end of the price band of Rs 290-296 the post-issue market cap of the stock on listing would be Rs3,400 crore and the post-issue price earnings ratio would be 25 times. The offer closes on June 25. The proceeds from fresh issues are planned to be utilised towards working capital requirement and other corporate purposes.

Have you been led to believe that multibaggers picked by popular investors are purely the result of skill, timing and foresight? Well, it’s often luck
Hold On
You are being redirected to another page,
Elevate Your Wealth with Professional Portfolio Management